Skip to contentA
Axim Biotechnologies, Inc.
A
AXIMAxim Biotechnologies, Inc. Q4 2019 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$782.42K$782.42Kderived+368.6% vs Q4 2018 Net Income-$1.44M-$1.44MderivedN/M vs Q4 2018 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Axim Biotechnologies, Inc. · CIK 1514946 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$128,926−22.2% Operating Incomederived-$1,253,517N/M Operating Cash Flowderived-$1,390,231N/M Margins · derivedGross margin16.5%−82.7 pt vs Q4 2018
Operating margin-160.2%+272.9 pt vs Q4 2018
Net margin-183.5%+402.7 pt vs Q4 2018
ended Dec 31, 2019 · filed May 14, 2020 · 135 d after period end